SecBot SecBot
SECBOTREPLAY Home › Report › ZYME

ZYME · Zymeworks announced that its partner Jazz Pharmaceuticals received FDA…

Zymeworks Inc. · 8-K filed Aug 25, 2026 at 10:54 ET

At the news

BULLISHIMPACT 8/10

8-K filed Aug 25, 2026 at 10:54 ET

Zymeworks announced that its partner Jazz Pharmaceuticals received FDA approval for two Ziihera (zanidatamab-hrii)-containing regimens for first-line HER2+ gastroesophageal adenocarcinoma (GEA). This approval triggers a $250 million milestone payment to Zymeworks, bringing total upfront and milestone payments from Jazz to $650 million, with up to $1.3 billion in additional milestones and tiered royalties of 10-20% on net sales remaining. This is the second FDA approval for zanidatamab in under two years, significantly de-risking the asset and providing substantial non-dilutive capital to fund Zymeworks' wholly-owned pipeline.

  • FDA approved two Ziihera-containing regimens for first-line HER2+ GEA, including with and without tislelizumab plus chemotherapy.
  • Zymeworks earned a $250 million milestone payment from Jazz Pharmaceuticals upon this approval.
  • Total upfront and milestone payments received from Jazz now total $650 million.
  • Zymeworks remains eligible for up to $1.3 billion in additional regulatory and commercial milestones plus tiered royalties of 10% to 20% on Jazz's net sales.

Replay the market's reaction

Step through every 5 minutes around the news, then see how it compares with similar events.

Subscribe for Full Access